In August 2020, the healthcare industry reported 59 deals worth $35.4 billion as compared to the last 12-month average (August 2019 to July 2020) of 73 deals worth $10 billion.
Deal value in the M&A market reported a surge in August 2020. Siemens Healthineers AG to acquire all outstanding shares of Varian Medical Systems for $177.50 per share or $16.4 billion in cash; Johnson & Johnson to acquire Momenta Pharmaceuticals, a biotechnology company for $52.5 per share in cash, representing a total equity value of $6.5 billion; Sanofi to acquire all of the outstanding shares of Principia Biopharma for $100 per share in cash, representing an aggregate equity value of approximately $3.6 billion were the three big-ticket deals which contributed 74 per cent of the total deal value during August 2020.
| Deal Date | Acquirer (s) | Target | Deal Value ($ million) |
| 2-Aug-20 | Siemens Healthineers AG (Germany) | Varian Medical Systems Inc (US) | 16,400.0 |
| 19-Aug-20 | Johnson & Johnson (US) | Varian Medical Momenta Pharmaceuticals Inc (US) | 6,500.0 |
| 17-Aug-20 | Sanofi (France) | Principia Biopharma Inc (US) | 3,680.0 |
| 31-Aug-20 | Nestle Health Science SA (Switzerland) | Aimmune Therapeutics Inc (US) | 2,600.0 |
| 24-Aug-20 | Acadia Pharmaceuticals Inc (US) | CerSci Therapeutics Inc (US) | 939.5 |
VC investments reported an increase in deal value in August 2020
The healthcare industry reported 100 venture capital (VC) deals worth $3.3 billion in August 2020, compared to the last 12-month average (August 2019 to July 2020) of 114 deals worth $2.3 billion.
Lepu Biotech, a biotechnology company specialised in tumour immunotherapy raising $186 million in series B round of financing to accelerate the research and development, clinical trials and product launches of its multiple anti-tumour drugs; Suzhou Sinovent Pharmaceuticals raising $144.5 million in series C financing to promote the ongoing clinical trials of its new products and Atomwise raising $123 million in series B round of financing to scale its AI technology platform and expand its pipeline for small molecule drug discovery are the major VC deals reported in August 2020.
| Deal Date | Acquirer (s) | Target | Deal Value ($ million) |
| 6-Aug-20 | Haitong Innovation Capital Management Co., Ltd.; Riverhead Capital Investment Management Co., Ltd.; SDIC Unity Capital Co., Ltd.; Ping An Capital; State New Central Enterprises Operating Investment Fund | Lepu Biotech (China) | 185.8 |
| 25-Aug-20 | Loyal Valley Innovation Capital LLC; China International Capital Corp Ltd; Oceanpine Capital; Jiuyo Capital Management Co., Ltd. Undisclosed Investor(s) | Suzhou Sinovent Pharmaceuticals Co Ltd (China) | 144.5 |
| 11-Aug-20 | AME Cloud Ventures; BV Investment Partners; Tencent Holdings Ltd; Y Combinator Management LLC; Dolby Family Ventures LP; Sanabil Investments; B Capital Group; Undisclosed Investor(s) | Atomwise Inc (US) | 123.0 |
| 24-Aug-20 | RA Capital Management, LP; Qiming Venture Partners; Lilly Asia ventures; Boxer Capital LLC; HBM Healthcare Investments AG | Suzhou Connect Biopharmaceuticals Ltd (China) | 115.0 |
| 10-Aug-20 | Wellington Management Company LLP; Undisclosed Investor(s); Atlas Venture Inc; Forbion Capital Partners Management Services BV; MPM Capital Inc; Vida Ventures LLC; Surveyor Capital Ltd; Logos Global Management LLC | Dyne Therapeutics Inc (US) | 115.0 |